Payment overview · 2025
General Payments
$202.32
9 reported records · 6 companies
Healthcare provider profile · identity verified
Kenneth Manchon, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ATLANTIS, FL · NPI 1073569398
Verified facts
What the public records show
CMS Open Payments records show Kenneth Manchon, MD received $202.32 in general payments during 2025 across 9 reported records.
Amgen Inc. accounted for 36.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $73.95 | 36.5% | 4 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $48.67 | 24.1% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $23.19 | 11.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.59 | 11.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.21 | 8.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.71 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $202.32 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $73.95 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $73.95 | 4 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $48.67 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $23.19 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 98 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
98 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 922 | 274 |
| Amlodipine Besylate | Amlodipine Besylate | 818 | 248 |
| Levothyroxine Sodium | Levothyroxine Sodium | 770 | 207 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 677 | 225 |
| Alprazolam | Alprazolam | 565 | 158 |
| Losartan Potassium | Losartan Potassium | 562 | 163 |
| Lisinopril | Lisinopril | 427 | 125 |
| Omeprazole | Omeprazole | 420 | 129 |
| Metoprolol Succinate | Metoprolol Succinate | 386 | 109 |
| Simvastatin | Simvastatin | 380 | 110 |
| Escitalopram Oxalate | Escitalopram Oxalate | 348 | 113 |
| Azithromycin | Azithromycin | 324 | 258 |
| Metformin Hcl | Metformin Hcl | 316 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 304 | 100 |
| Famotidine | Famotidine | 276 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 251 | 83 |
| Temazepam | Temazepam | 233 | 55 |
| Gabapentin | Gabapentin | 232 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 222 | 73 |
| Zolpidem Tartrate | Zolpidem Tartrate | 187 | 67 |
| Eliquis | Apixaban | 185 | 44 |
| Furosemide | Furosemide | 178 | 58 |
| Potassium Chloride | Potassium Chloride | 168 | 59 |
| Sertraline Hcl | Sertraline Hcl | 161 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 39 |
| Montelukast Sodium | Montelukast Sodium | 151 | 43 |
| Ezetimibe | Ezetimibe | 138 | 46 |
| Lorazepam | Lorazepam | 137 | 31 |
| Glipizide Er | Glipizide | 131 | 34 |
| Tramadol Hcl | Tramadol Hcl | 125 | 55 |
| Clonazepam | Clonazepam | 123 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 123 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 32 |
| Carvedilol | Carvedilol | 118 | 39 |
| Valsartan | Valsartan | 112 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 108 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 108 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | 28 |
| Atenolol | Atenolol | 101 | 31 |
| Ozempic | Semaglutide | 98 | 22 |
| Allopurinol | Allopurinol | 97 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 34 |
| Diazepam | Diazepam | 95 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 92 | 28 |
| Glipizide | Glipizide | 91 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 26 |
| Trazodone Hcl | Trazodone Hcl | 90 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 85 | 27 |
| Synthroid | Levothyroxine Sodium | 85 | 26 |
| Finasteride | Finasteride | 84 | 25 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 80 | 64 |
| Alendronate Sodium | Alendronate Sodium | 78 | 24 |
| Methylprednisolone | Methylprednisolone | 76 | 63 |
| Jardiance | Empagliflozin | 73 | 23 |
| Spironolactone | Spironolactone | 72 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 29 |
| Nifedipine Er | Nifedipine | 69 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 69 | 11 |
| Bupropion Xl | Bupropion Hcl | 67 | 22 |
| Metformin Hcl Er | Metformin Hcl | 66 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 50 |
| Xarelto | Rivaroxaban | 58 | 13 |
| Celecoxib | Celecoxib | 57 | 22 |
| Meloxicam | Meloxicam | 57 | 23 |
| Prednisone | Prednisone | 56 | 30 |
| Pregabalin | Pregabalin | 56 | 15 |
| Cefuroxime | Cefuroxime Axetil | 54 | 49 |
| Ondansetron Odt | Ondansetron | 54 | 34 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 50 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 12 |
| Valacyclovir | Valacyclovir Hcl | 48 | 27 |
| Fenofibrate | Fenofibrate | 47 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 32 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 32 |
| Meclizine Hcl | Meclizine Hcl | 39 | 25 |
| Ramipril | Ramipril | 38 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 37 | 14 |
| Dutasteride | Dutasteride | 37 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 22 |
| Benazepril Hcl | Benazepril Hcl | 35 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 35 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | 12 |
| Amoxicillin | Amoxicillin | 30 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 15 |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 11 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 24 | 13 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Methimazole | Methimazole | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 12 |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 13 |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Fluvastatin Er | Fluvastatin Sodium | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 12 |
| Naproxen | Naproxen | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 16 | suppressed |
| Trandolapril | Trandolapril | 16 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Glyburide | Glyburide | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Buprenorphine | Buprenorphine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Klor-Con 10 | Potassium Chloride | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $202.32 · 9 records | Amgen Inc. | AREXVY, Dexcom G6 Transmitter, Integra, Integra Dermal Regeneration Template, OTEZLA, Ozempic, PRIMATRIX, REPATHA, Rybelsus, SHINGRIX, SX-ONE MICROKNIFE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error